From: Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali
 | Estimate | Std. error | z value | OR (95% CI) | p-value |
---|---|---|---|---|---|
Artesunate + amodiaquine | |||||
 Intercept | − 0.62 | 2.46 | − 0.25 | 0.54 (0.004, 83.21) | 0.80 |
 Underweight | − 0.18 | 1.19 | − 0.15 | 0.84 (0.11, 17.69) | 0.88 |
 Overweight | − 1.54 | 0.66 | − 2.34 | 0.21 (0.06, 0.76) | 0.02 |
 Parasitaemia | 1.06e−07 | 1.15e−05 | 0.009 | 1 (0.99, 1) | 0.99 |
 ALAT | − 0.02 | 0.01 | − 1.21 | 0.98 (0.95, 1.00) | 0.22 |
 ASAT | − 0.002 | 0.01 | − 0.22 | 0.99 (0.98, 1.02) | 0.82 |
 Creatinine | 0.75 | 1.12 | 0.67 | 2.12 (0.59, 50.83) | 0.50 |
 Hb level | 0.27 | 0.21 | 1.29 | 1.31 (0.87, 2.01) | 0.19 |
Artesunate + sulfadoxine–pyrimethamine | |||||
 Intercept | 0.75 | 3.04 | 0.25 | 2.12 (0.005, 1.00e+03) | 0.80 |
 Underweight | − 0.33 | 1.29 | − 0.26 | 0.72 (0.07, 16.8) | 0.79 |
 Overweight | − 0.19 | 1.02 | 0.19 | 1.22 (0.17, 11.2) | 0.85 |
 Parasitaemia | − 1.39e−05 | 1.65e−05 | − 0.84 | 0.99 (0.99, 1) | 0.40 |
 ALAT | 0.03 | 0.05 | 0.63 | 1.03 (0.94, 1.16) | 0.53 |
 ASAT | − 0.003 | 0.03 | − 0.08 | 1 (0.95, 1.07) | 0.53 |
 Creatinine | 5.91 | 3.22 | 1.84 | 369.65 (1.39, 4.8e+05) | 0.07 |
 Hb level | − 0.16 | 0.29 | − 0.56 | 0.99 (0.47, 1.49) | 0.58 |
Artesunate in monotherapy | |||||
 Intercept | − 3.56 | 1.97 | − 1.80 | 0.03 (0.0005, 1.18) | 0.07 |
 Underweight | 1.14 | 0.94 | 1.21 | 3.11 (0.56, 25.64) | 0.23 |
 Overweight | 0.46 | 0.69 | 0.67 | 1.58 (0.42, 6.44) | 0.50 |
 Parasitaemia | 3.73e−06 | 9.42e−06 | 0.39 | 1 (0.99, 1) | 0.69 |
 ALAT | − 0.046 | 0.02 | − 2.26 | 0.95 (0.91, 0.99) | 0.02 |
 ASAT | 0.003 | 0.008 | 1.03 | 1.01 (0.98, 1.02) | 0.31 |
 Creatinine | 3.39 | 1.83 | 1.85 | 29.77 (1.71, 2088.11) | 0.06 |
 Hb level | 0.24 | 0.17 | 1.49 | 1.27 (0.93, 1.77) | 0.14 |